Immunology

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
Zeile 2: Zeile 2:
  
 
'''Antibody-dependent enhancement'''
 
'''Antibody-dependent enhancement'''
 +
 +
{{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}}
 +
{{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}}
 
{{ttp|p=31826992|t=2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |pdf=|usr=}}''antibodies target one serotype of viruses but only subneutralize another, leading to antibody-dependend enhancement of the latter viruses.''
 
{{ttp|p=31826992|t=2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry |pdf=|usr=}}''antibodies target one serotype of viruses but only subneutralize another, leading to antibody-dependend enhancement of the latter viruses.''
 
{{ttp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}} ade
 
{{ttp|p=32317716|t=ä. The potential danger of suboptimal antibody responses in COVID-19 |pdf=|usr=}} ade
 
{{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
 
{{tp|p=32346094|t=ä. COVID-19 vaccine design: the Janus face of immune enhancement |pdf=|usr=}}
 +
{{tp|p=32303697|t=ä. Will we see protection or reinfection in COVID-19?|pdf=|usr=}}
 +
 +
  
 
'''Innate sensing of infection'''
 
'''Innate sensing of infection'''
 
{{ttp|p=32291557|t=ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |pdf=|usr=}}
 
{{ttp|p=32291557|t=ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells |pdf=|usr=}}
 
{{tp|p=32198201|t=2020. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors |pdf=|usr=}}
 
{{tp|p=32198201|t=2020. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors |pdf=|usr=}}
−
 
 
{{tp|p=32374430|t=2020. DC/L-SIGNs of Hope in the COVID-19 Pandemic |pdf=|usr=}}
 
{{tp|p=32374430|t=2020. DC/L-SIGNs of Hope in the COVID-19 Pandemic |pdf=|usr=}}
 +
{{tp|p=32361001|t=ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes |pdf=|usr=}}
 +
{{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}}
 +
{{ttp|p=32407669|t=ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |pdf=|usr=}}
 +
 +
'''integrative work'''
 
*[https://www.cell.com/action/showPdf?pii=S1074-7613%2820%2930183-7 rev. on covid immunology]
 
*[https://www.cell.com/action/showPdf?pii=S1074-7613%2820%2930183-7 rev. on covid immunology]
 +
{{tp|p=32205856|t=2020. COVID-19 infection: the perspectives on immune responses |pdf=|usr=}}
 +
{{tp|p=32359396|t=ä. A Dynamic Immune Response Shapes COVID-19 Progression |pdf=|usr=}}
 +
 +
'''covid modulates the immune system'''
 
{{tp|p=32364527|t=2020. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2 |pdf=|usr=}}
 
{{tp|p=32364527|t=2020. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2 |pdf=|usr=}}
 +
{{tp|p=32172672|t=2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses |pdf=|usr=}}
 +
{{tp|p=32315725|t=ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China |pdf=|usr=}}
 +
{{ttp|p=32355328|t=ä. Impaired interferon signature in severe COVID-19 |pdf=|usr=}}
 +
{{tp|p=32375560|t=2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study |pdf=|usr=}}
 +
{{tp|p=32376308|t=ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}}
 +
{{ttp|p=32236983|t=2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |pdf=|usr=}}
 +
 +
 +
'''mediators'''
 +
{{tp|p=32360285|t=ä. Type I IFN immunoprofiling in COVID-19 patients |pdf=|usr=}}
 +
{{ttp|p=32376393|t=ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms |pdf=|usr=}}
 +
{{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}}
 +
{{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}}
 +
 +
 +
 +
'''plasmacytoid dendritic cells'''
 +
{{tp|p=32298486|t=2020. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19) |pdf=|usr=}}
 +
 +
'''immune cell subpopulations'''
 
{{tp|p=32282871|t=ä. Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32282871|t=ä. Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
−
{{tp|p=32371101|t=ä. The correlation between SARS-CoV-2 infection and rheumatic disease |pdf=|usr=}}
 
−
{{tp|p=32205186|t=2020. COVID-19 infection and rheumatoid arthritis: Faraway, so close!|pdf=|usr=}}
 
−
{{tp|p=32308263|t=2020. CoViD-19 Immunopathology and Immunotherapy |pdf=|usr=}}
 
 
{{tp|p=32325421|t=2020. Increased expression of CD8 marker on T-cells in COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32325421|t=2020. Increased expression of CD8 marker on T-cells in COVID-19 patients |pdf=|usr=}}
−
{{tp|p=32205856|t=2020. COVID-19 infection: the perspectives on immune responses |pdf=|usr=}}
 
−
{{tp|p=32359396|t=ä. A Dynamic Immune Response Shapes COVID-19 Progression |pdf=|usr=}}
 
 
{{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
 
{{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
−
{{tp|p=32320677|t=ä. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure |pdf=|usr=}}
 
 
{{tp|p=32346099|t=ä. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32346099|t=ä. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients |pdf=|usr=}}
−
 
 
{{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
 
{{tp|p=32339487|t=2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China |pdf=|usr=}}
−
{{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}}
 
−
{{tp|p=32161940|t=ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China |pdf=|usr=}}
 
−
{{tp|p=32280952|t=ä. Good IgA bad IgG in SARS-CoV-2 infection?|pdf=|usr=}}
 
−
{{tp|p=32354367|t=2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia |pdf=|usr=}}
 
−
 
 
{{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}}
 
{{tp|p=32361250|t=2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients |pdf=|usr=}}
−
{{tp|p=32368728|t=ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study |pdf=|usr=}}
 
 
{{tp|p=32228226|t=2020. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32228226|t=2020. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients |pdf=|usr=}}
 
{{tp|p=32196410|t=2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection?a review of immune  changes in patients with viral pneumonia |pdf=|usr=}}
 
{{tp|p=32196410|t=2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection?a review of immune  changes in patients with viral pneumonia |pdf=|usr=}}
−
{{tp|p=32172672|t=2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses |pdf=|usr=}}
 
−
 
−
{{tp|p=32348472|t=ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?|pdf=|usr=}}
 
−
 
−
{{tp|p=32360285|t=ä. Type I IFN immunoprofiling in COVID-19 patients |pdf=|usr=}}
 
−
{{tp|p=32344056|t=ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination |pdf=|usr=}}
 
 
{{tp|p=32333914|t=ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia |pdf=|usr=}}
 
{{tp|p=32333914|t=ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia |pdf=|usr=}}
−
{{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32344320|t=ä. The clinical course and its correlated immune status in COVID-19 pneumonia |pdf=|usr=}}
 
{{tp|p=32344320|t=ä. The clinical course and its correlated immune status in COVID-19 pneumonia |pdf=|usr=}}
−
{{tp|p=32353870|t=2020. The many faces of the anti-COVID immune response |pdf=|usr=}}
 
−
 
−
{{tp|p=32277967|t=ä. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
 
 
{{tp|p=32325129|t=ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia |pdf=|usr=}}
 
{{tp|p=32325129|t=ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia |pdf=|usr=}}
−
{{tp|p=32315725|t=ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China |pdf=|usr=}}
 
 
{{tp|p=32283159|t=ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 |pdf=|usr=}}
 
{{tp|p=32283159|t=ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 |pdf=|usr=}}
−
{{tp|p=32283164|t=ä. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China |pdf=|usr=}}
 
−
{{tp|p=32283162|t=ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 |pdf=|usr=}}
 
−
{{tp|p=32358956|t=ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19 |pdf=|usr=}}
 
−
 
 
{{tp|p=32227123|t=ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia |pdf=|usr=}}
 
{{tp|p=32227123|t=ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia |pdf=|usr=}}
 +
{{tp|p=32343510|t=2020. COVID-19: are T lymphocytes simply watching?|pdf=|usr=}}
 +
{{tp|p=32379887|t=ä. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19 |pdf=|usr=}}
 +
{{tp|p=32297671|t=2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients |pdf=|usr=}}
 +
{{tp|p=32352397|t=2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study |pdf=|usr=}}
 +
{{tp|p=32379199|t=2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes |pdf=|usr=}}
 +
{{tp|p=32296069|t=2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study |pdf=|usr=}}
  
−
{{tp|p=31981224|t=2020. Coronavirus infections and immune responses |pdf=|usr=}}
+
{{tp|p=32297828|t=2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 |pdf=|usr=}}
−
{{tp|p=32198005|t=2020. A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic |pdf=|usr=}}
+
{{tp|p=32370466|t=2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19  |pdf=|usr=}}
−
{{tp|p=32282863|t=ä. Molecular immune pathogenesis and diagnosis of COVID-19 |pdf=|usr=}}
+
{{tp|p=32114745|t=2020.  Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19  |pdf=|usr=}}
 +
{{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
  
−
{{tp|p=32292901|t=2020. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity |pdf=|usr=}}
 
−
{{tp|p=32303592|t=2020. Human leukocyte antigen susceptibility map for SARS-CoV-2 |pdf=|usr=}}
 
−
{{tp|p=32215589|t=2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia |pdf=|usr=}}
 
−
{{tp|p=32324595|t=2020. The laboratory tests and host immunity of COVID-19 patients with different severity of illness |pdf=|usr=}}
 
  
−
{{tp|p=32259560|t=ä. Interleukin-6 as a potential biomarker of COVID-19 progression |pdf=|usr=}}
+
'''t cell exhaustion'''
−
{{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}}
+
{{tp|p=32249845|t=ä. Fighting COVID-19 exhausts T cells |pdf=|usr=}}
−
{{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}}
+
 
−
{{tp|p=32361001|t=ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes |pdf=|usr=}}
+
{{ttp|p=32203188|t=2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |pdf=|usr=}}
−
{{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}}
+
{{ttp|p=32203186|t=2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |pdf=|usr=}}
−
{{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}}
+
 
 +
 
 +
 
 +
'''immunopathology'''
 +
{{tp|p=32371101|t=ä. The correlation between SARS-CoV-2 infection and rheumatic disease |pdf=|usr=}}
 +
{{tp|p=32205186|t=2020. COVID-19 infection and rheumatoid arthritis: Faraway, so close!|pdf=|usr=}}
 +
{{tp|p=32308263|t=2020. CoViD-19 Immunopathology and Immunotherapy |pdf=|usr=}}
 +
{{tp|p=32320677|t=ä. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure |pdf=|usr=}}
 +
{{tp|p=32161940|t=ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China |pdf=|usr=}}
 +
{{tp|p=32282863|t=ä. Molecular immune pathogenesis and diagnosis of COVID-19 |pdf=|usr=}}
 
{{tp|p=32321823|t=2020. COVID-19: an Immunopathological View |pdf=|usr=}}
 
{{tp|p=32321823|t=2020. COVID-19: an Immunopathological View |pdf=|usr=}}
−
{{tp|p=32284614|t=ä. Breadth of concomitant immune responses prior to patient recovery: a case report  of non-severe COVID-19 |pdf=|usr=}}
 
 
{{tp|p=32273594|t=ä. COVID-19: immunopathology and its implications for therapy |pdf=|usr=}}
 
{{tp|p=32273594|t=ä. COVID-19: immunopathology and its implications for therapy |pdf=|usr=}}
−
{{tp|p=32249845|t=ä. Fighting COVID-19 exhausts T cells |pdf=|usr=}}
+
{{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}}
 +
{{tp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}}
 +
 
 +
 
 +
'''antiviral immune response'''
 +
{{tp|p=32280952|t=ä. Good IgA bad IgG in SARS-CoV-2 infection?|pdf=|usr=}}
 +
{{tp|p=32353870|t=2020. The many faces of the anti-COVID immune response |pdf=|usr=}}
 +
{{tp|p=32358956|t=ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19 |pdf=|usr=}}
 +
{{tp|p=31981224|t=2020. Coronavirus infections and immune responses |pdf=|usr=}}
 +
{{tp|p=32198005|t=2020. A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course  and anti-SARS-CoV-2 IgG dynamic |pdf=|usr=}}
 +
{{tp|p=32284614|t=ä. Breadth of concomitant immune responses prior to patient recovery: a case report  of non-severe COVID-19 |pdf=|usr=}}
 
{{tp|p=32355329|t=ä. SARS-CoV-2-reactive T cells in patients and healthy donors |pdf=|usr=}}
 
{{tp|p=32355329|t=ä. SARS-CoV-2-reactive T cells in patients and healthy donors |pdf=|usr=}}
−
{{ttp|p=32355328|t=ä. Impaired interferon signature in severe COVID-19 |pdf=|usr=}}
 
−
{{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}}
 
 
{{tp|p=32346091|t=ä. Neutralizing antibody response in mild COVID-19 |pdf=|usr=}}
 
{{tp|p=32346091|t=ä. Neutralizing antibody response in mild COVID-19 |pdf=|usr=}}
−
{{tp|p=32303697|t=ä. Will we see protection or reinfection in COVID-19?|pdf=|usr=}}
+
{{tp|p=32356908|t=2020. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis |pdf=|usr=}}
−
{{tp|p=32303696|t=ä. Macrophages: a Trojan horse in COVID-19?|pdf=|usr=}}
+
{{ttp|p=32343415|t=2020. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients |pdf=|usr=}}
 +
{{tp|p=32330332|t=2020. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic |pdf=|usr=}}
 +
{{tp|p=32267987|t=2020. Immune responses and pathogenesis of SARS?CoV?2 during an outbreak in Iran: Comparison with SARS and MERS |pdf=|usr=}}
 +
{{tp|p=32348715|t=2020. B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020 |pdf=|usr=}}
  
−
{{tp|p=32343510|t=2020. COVID-19: are T lymphocytes simply watching?|pdf=|usr=}}
+
 
 +
 
 +
'''secondary autoimmunity'''
 +
{{tp|p=32292901|t=2020. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity |pdf=|usr=}}
 +
{{tp|p=32220633|t=2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?|pdf=|usr=}}
 +
{{tp|p=32315487|t=2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19 |pdf=|usr=}}
 +
{{ttp|p=32314313|t=2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?|pdf=|usr=}}
 +
 
 +
'''Thymus'''
 
{{tp|p=32340873|t=ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype |pdf=|usr=}}
 
{{tp|p=32340873|t=ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype |pdf=|usr=}}
 
{{tp|p=32317217|t=ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype |pdf=|usr=}}
 
{{tp|p=32317217|t=ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype |pdf=|usr=}}
  
 +
 +
'''Eosinopenia, Eosinophilia'''
 +
{{tp|p=32368728|t=ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study |pdf=|usr=}}
 +
{{tp|p=32344056|t=ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination |pdf=|usr=}}
 +
{{tp|p=32369190|t=2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series |pdf=|usr=}}
 
{{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
 
{{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
 
{{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}}
  
−
{{tp|p=32292530|t=2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan|pdf=|usr=}}
+
'''Immunogenetics'''
 +
{{tp|p=32303592|t=2020. Human leukocyte antigen susceptibility map for SARS-CoV-2 |pdf=|usr=}}
 +
{{tp|p=32343152|t=2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases |pdf=|usr=}}
 +
 
 +
 
  
−
{{tp|p=32369190|t=2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series |pdf=|usr=}}
 
−
{{tp|p=32298486|t=2020. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19) |pdf=|usr=}}
 
−
{{tp|p=32360743|t=ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 |pdf=|usr=}}
 
  
−
{{ttp|p=32376393|t=ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms |pdf=|usr=}}
 
−
{{tp|p=32220633|t=2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?|pdf=|usr=}}
 
−
{{tp|p=32297671|t=2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients |pdf=|usr=}}
 
−
{{tp|p=32311762|t=2020. SARS-CoV-2: a new aetiology for atypical lymphocytes |pdf=|usr=}}
 
−
{{tp|p=32297330|t=2020. Reactive lymphocytes in patients with Covid-19 |pdf=|usr=}}
 
−
{{ttp|p=32203188|t=2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients |pdf=|usr=}}
 
−
{{ttp|p=32203186|t=2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients |pdf=|usr=}}
 
−
{{ttp|p=32314313|t=2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?|pdf=|usr=}}
 
−
{{tp|p=32375560|t=2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study |pdf=|usr=}}
 
  
−
{{tp|p=32119647|t=2020. Laboratory abnormalities in patients with COVID-2019 infection |pdf=|usr=}}
 
−
{{tp|p=32172227|t=2020. Laboratory abnormalities in children with novel coronavirus disease 2019 |pdf=|usr=}}
 
−
{{tp|p=32352397|t=2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study |pdf=|usr=}}
 
−
{{tp|p=32242828|t=2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan |pdf=|usr=}}
 
−
{{tp|p=32301746|t=2020. Routine blood tests as a potential diagnostic tool for COVID-19 |pdf=|usr=}}
 
−
{{ttp|p=32286245|t=2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis |pdf=|usr=}}
 
−
{{tp|p=32365221|t=2020. Using IL-2R/lymphocytes for predicting the clinical progression of patients with  COVID-19 |pdf=|usr=}}
 
−
{{tp|p=32315487|t=2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19 |pdf=|usr=}}
 
−
{{tp|p=32343152|t=2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases |pdf=|usr=}}
 
−
{{tp|p=32376308|t=ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis |pdf=|usr=}}
 
  
−
{{tp|p=32379887|t=ä. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19 |pdf=|usr=}}
 
−
{{tp|p=32181911|t=ä. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID?19 |pdf=|usr=}}
 
−
{{tp|p=32356908|t=2020. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis |pdf=|usr=}}
 
−
{{tp|p=32347972|t=2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19 |pdf=|usr=}}
 
−
{{tp|p=32343415|t=2020. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients |pdf=|usr=}}
 
−
{{tp|p=32297995|t=2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients |pdf=|usr=}}
 
−
{{tp|p=32281668|t=2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early |pdf=|usr=}}
 
  
−
{{tp|p=32376901|t=ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |pdf=|usr=}}
 
−
{{tp|p=32348636|t=2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva |pdf=|usr=}}
 
−
{{ttp|p=32359201|t=2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |pdf=|usr=}}
 
−
{{tp|p=32330332|t=2020. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic |pdf=|usr=}}
 
−
{{tp|p=32379199|t=2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes |pdf=|usr=}}
 
−
{{tp|p=32267987|t=2020. Immune responses and pathogenesis of SARS?CoV?2 during an outbreak in Iran: Comparison with SARS and MERS |pdf=|usr=}}
 
−
{{tp|p=32296069|t=2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study |pdf=|usr=}}
 
−
{{ttp|p=32236983|t=2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection |pdf=|usr=}}
 
−
{{tp|p=32348715|t=2020. B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020 |pdf=|usr=}}
 
−
{{tp|p=32297828|t=2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19 |pdf=|usr=}}
 
−
{{tp|p=32370466|t=2020.  Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19  |pdf=|usr=}}
 
−
{{tp|p=32114745|t=2020.  Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19  |pdf=|usr=}}
 
  
−
{{tp|p=32377375|t=2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing |pdf=|usr=}}
 
−
{{tp|p=32407669|t=ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients |pdf=|usr=}}
 
 
{{tp|p=32382126|t=ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients |pdf=|usr=}}
 
{{tp|p=32382126|t=ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients |pdf=|usr=}}
 
{{tp|p=32382127|t=ä. NKG2A and COVID-19: another brick in the wall |pdf=|usr=}} ''we dont need no isolation we dont need no folks control''
 
{{tp|p=32382127|t=ä. NKG2A and COVID-19: another brick in the wall |pdf=|usr=}} ''we dont need no isolation we dont need no folks control''
Zeile 167: Zeile 169:
 
{{tp|p=C7107806|t=ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury |pdf=|usr=}}
 
{{tp|p=C7107806|t=ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury |pdf=|usr=}}
 
{{tp|p=32455147|t=ä. C reactive protein level may predict the risk of COVID-19 aggravation |pdf=|usr=}}
 
{{tp|p=32455147|t=ä. C reactive protein level may predict the risk of COVID-19 aggravation |pdf=|usr=}}
−
{{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}}
+
 
  
 
{{tp|p=32452410|t=2020. Association of viral load with serum biomakers among COVID-19 cases |pdf=|usr=}}
 
{{tp|p=32452410|t=2020. Association of viral load with serum biomakers among COVID-19 cases |pdf=|usr=}}
 +
{{tp|p=32215589|t=2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia |pdf=|usr=}}
 +
{{tp|p=32360743|t=ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19 |pdf=|usr=}}
 +
{{tp|p=32292530|t=2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan|pdf=|usr=}}
 +
{{tp|p=32346093|t=ä. The trinity of COVID-19: immunity, inflammation and intervention |pdf=|usr=}}
 +
{{tp|p=32348636|t=2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva |pdf=|usr=}}
 +
{{tp|p=32297330|t=2020. Reactive lymphocytes in patients with Covid-19 |pdf=|usr=}}
 +
{{tp|p=32311762|t=2020. SARS-CoV-2: a new aetiology for atypical lymphocytes |pdf=|usr=}}
 +
 +
 +
{{ttp|p=32359201|t=2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures |pdf=|usr=}}

Version vom 22. Juni 2020, 09:37 Uhr

coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.

Antibody-dependent enhancement

32092539 2020. Is COVID-19 receiving ADE from other coronaviruses?


32268188 ä. It is too soon to attribute ADE to COVID-19

31826992 2020. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
antibodies target one serotype of viruses but only subneutralize another, leading to antibody-dependend enhancement of the latter viruses.
32317716 ä. The potential danger of suboptimal antibody responses in COVID-19
ade


32346094 ä. COVID-19 vaccine design: the Janus face of immune enhancement
32303697 ä. Will we see protection or reinfection in COVID-19?


Innate sensing of infection

32291557 ä. SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells


32198201 2020. Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors
32374430 2020. DC/L-SIGNs of Hope in the COVID-19 Pandemic
32361001 ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes
32248387 ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution

32407669 ä. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

integrative work


32205856 2020. COVID-19 infection: the perspectives on immune responses
32359396 ä. A Dynamic Immune Response Shapes COVID-19 Progression

covid modulates the immune system
32364527 2020. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2
32172672 2020. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses
32315725 ä. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan, China

32355328 ä. Impaired interferon signature in severe COVID-19


32375560 2020. SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights from the ERS-COVID-19 Study
32376308 ä. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis

32236983 2020. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection


mediators
32360285 ä. Type I IFN immunoprofiling in COVID-19 patients

32376393 ä. Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms
32305501 ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement


32414693 2020. Interleukin-6 levels in children developing SARS-CoV-2 infection


plasmacytoid dendritic cells
32298486 2020. Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19)

immune cell subpopulations
32282871 ä. Inflammatory Response Cells During Acute Respiratory Distress Syndrome in Patients With Coronavirus Disease 2019 (COVID-19)
32325421 2020. Increased expression of CD8 marker on T-cells in COVID-19 patients
32377375 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
32346099 ä. High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients
32339487 2020. Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China
32361250 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
32228226 2020. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients
32196410 2020. Hypothesis for potential pathogenesis of SARS-CoV-2 infection?a review of immune changes in patients with viral pneumonia
32333914 ä. A possible role for B cells in COVID-19?: Lesson from patients with Agammaglobulinemia
32344320 ä. The clinical course and its correlated immune status in COVID-19 pneumonia
32325129 ä. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia
32283159 ä. Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19
32227123 ä. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia
32343510 2020. COVID-19: are T lymphocytes simply watching?
32379887 ä. T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19
32297671 2020. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients
32352397 2020. The hemocyte counts as a potential biomarker for predicting disease progression in COVID-19: a retrospective study
32379199 2020. A Typical Case of Critically Ill Infant of Coronavirus Disease 2019 With Persistent Reduction of T Lymphocytes
32296069 2020. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study


32297828 2020. Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19
32370466 2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19
32114745 2020. Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19
32377375 2020. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing


t cell exhaustion
32249845 ä. Fighting COVID-19 exhausts T cells

32203188 2020. Functional exhaustion of antiviral lymphocytes in COVID-19 patients
32203186 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients


immunopathology
32371101 ä. The correlation between SARS-CoV-2 infection and rheumatic disease
32205186 2020. COVID-19 infection and rheumatoid arthritis: Faraway, so close!
32308263 2020. CoViD-19 Immunopathology and Immunotherapy
32320677 ä. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
32161940 ä. Dysregulation of immune response in patients with COVID-19 in Wuhan, China
32282863 ä. Molecular immune pathogenesis and diagnosis of COVID-19
32321823 2020. COVID-19: an Immunopathological View
32273594 ä. COVID-19: immunopathology and its implications for therapy
32303696 ä. Macrophages: a Trojan horse in COVID-19?
32376901 ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages


antiviral immune response
32280952 ä. Good IgA bad IgG in SARS-CoV-2 infection?
32353870 2020. The many faces of the anti-COVID immune response
32358956 ä. Longitudinal Change of SARS-Cov2 Antibodies in Patients with COVID-19
31981224 2020. Coronavirus infections and immune responses
32198005 2020. A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic
32284614 ä. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
32355329 ä. SARS-CoV-2-reactive T cells in patients and healthy donors
32346091 ä. Neutralizing antibody response in mild COVID-19
32356908 2020. Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis

32343415 2020. Long-term coexistence of SARS-CoV-2 with antibody response in COVID-19 patients


32330332 2020. SARS-CoV-2 infection in children - Understanding the immune responses and controlling the pandemic
32267987 2020. Immune responses and pathogenesis of SARS?CoV?2 during an outbreak in Iran: Comparison with SARS and MERS
32348715 2020. B Cells, Viruses, and the SARS-CoV-2/COVID-19 Pandemic of 2020


secondary autoimmunity
32292901 2020. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity
32220633 2020. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects?
32315487 2020. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19

32314313 2020. Is COVID-19 a proteiform disease inducing also molecular mimicry phenomena?

Thymus
32340873 ä. Reply: Thymopoiesis, inflamm-aging, and COVID-19 phenotype
32317217 ä. Role of thymopoiesis and inflamm-aging in COVID-19 phenotype


Eosinopenia, Eosinophilia
32368728 ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study
32344056 ä. Eosinophil Responses During COVID-19 Infections and Coronavirus Vaccination
32369190 2020. COVID-19, chronic inflammatory respiratory diseases and eosinophils - Observationsfrom reported clinical case series

32315429 ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19)


32315421 ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19)

Immunogenetics
32303592 2020. Human leukocyte antigen susceptibility map for SARS-CoV-2
32343152 2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases






32382126 ä. Protective humoral immunity in SARS-CoV-2 infected pediatric patients
32382127 ä. NKG2A and COVID-19: another brick in the wall we dont need no isolation we dont need no folks control
32235915 ä. COVID-19: a new challenge for human beings

32203188 ä. Functional exhaustion of antiviral lymphocytes in COVID-19 patients
32203186 ä. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients


32132669 ä. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
C7064018 ä. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses


32200654 2020. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection
32361250 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

32156572 2020. Viroporins and inflammasomes: A key to understand virus-induced inflammation
C7200337 ä. Immunology of COVID-19: current state of the science


32376309 2020. Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients

32376308 2020. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis


32389543 ä. COVID-19 and molecular mimicry: The Columbus? egg?
32438257 2020. SARS-CoV-2 and enhancing antibodies

32073157 2020. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus?associated illnesses


30715745 2019. (+)Th17 serum cytokines in relation to laboratory?confirmed respiratory viral infection: A pilot study

32408068 2020. What about the original antigenic sin of the humans versus SARS-CoV-2?
the term «original antigenic sin» (OAS) was coined by T. Francis Jr at the Michigan University in the late 1950s to describe patterns of antibody response to influenza vaccination...
32286536 ä. Coronaviruses hijack the complement system
host complement activator MASP2 as a target of the N protein of all three viruses


32372779 2020. Do you become immune once you have been infected?
32372807 2020. The fever paradox
32416412 2020. Free DNA, a reason for severe COVID-19 infection?
32388390 2020. The powerful immune system against powerful COVID-19: A hypothesis

32376901 ä. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages


C7107806 ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury
32455147 ä. C reactive protein level may predict the risk of COVID-19 aggravation



32452410 2020. Association of viral load with serum biomakers among COVID-19 cases
32215589 2020. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia
32360743 ä. Lower detection rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19
32292530 2020. Respiratory diseases, allergy and COVID-19 infection. First news from Wuhan
32346093 ä. The trinity of COVID-19: immunity, inflammation and intervention
32348636 2020. Hyposalivation as a potential risk for SARS-CoV-2 infection: Inhibitory role of saliva
32297330 2020. Reactive lymphocytes in patients with Covid-19
32311762 2020. SARS-CoV-2: a new aetiology for atypical lymphocytes


32359201 2020. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures
Von „http://coviki.org/cov/index.php?title=Immunology&oldid=2877“
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis